AU2004268112A1 - Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 - Google Patents

Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 Download PDF

Info

Publication number
AU2004268112A1
AU2004268112A1 AU2004268112A AU2004268112A AU2004268112A1 AU 2004268112 A1 AU2004268112 A1 AU 2004268112A1 AU 2004268112 A AU2004268112 A AU 2004268112A AU 2004268112 A AU2004268112 A AU 2004268112A AU 2004268112 A1 AU2004268112 A1 AU 2004268112A1
Authority
AU
Australia
Prior art keywords
effective amount
pharmaceutically acceptable
pct
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004268112A
Other languages
English (en)
Inventor
Celine Bonnefous
Steven P. Govek
John H. Hutchinson
Theodore M. Kamenecka
Jean-Michel Vernier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2004268112A1 publication Critical patent/AU2004268112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Manufacturing & Machinery (AREA)
  • Psychiatry (AREA)
  • Ceramic Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2004268112A 2003-09-02 2004-08-27 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 Abandoned AU2004268112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49962703P 2003-09-02 2003-09-02
US60/499,627 2003-09-02
PCT/US2004/027916 WO2005021529A1 (en) 2003-09-02 2004-08-27 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5

Publications (1)

Publication Number Publication Date
AU2004268112A1 true AU2004268112A1 (en) 2005-03-10

Family

ID=34272848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004268112A Abandoned AU2004268112A1 (en) 2003-09-02 2004-08-27 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5

Country Status (7)

Country Link
US (1) US20070027321A1 (https=)
EP (1) EP1664018A1 (https=)
JP (1) JP2007504229A (https=)
CN (1) CN1845915A (https=)
AU (1) AU2004268112A1 (https=)
CA (1) CA2537141A1 (https=)
WO (1) WO2005021529A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60223720T2 (de) * 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CN100387594C (zh) * 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
CA2520863A1 (en) * 2003-04-03 2004-10-14 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
JP2009526868A (ja) * 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
MY146992A (en) * 2007-06-18 2012-10-15 Richter Gedeon Nyrt Sulfonyl-quinoline derivatives
EP2573087A1 (en) 2007-09-21 2013-03-27 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
BRPI0818658A2 (pt) * 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
US7800382B2 (en) 2007-12-19 2010-09-21 AEHR Test Ststems System for testing an integrated circuit of a device and its method of use
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
ES2397934T3 (es) * 2008-12-17 2013-03-12 Amgen Inc. Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
US8030957B2 (en) 2009-03-25 2011-10-04 Aehr Test Systems System for testing an integrated circuit of a device and its method of use
JPWO2012121314A1 (ja) * 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
JP5934782B2 (ja) 2011-05-04 2016-06-15 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アミノ−ピリジン含有脾臓チロシンキナーゼ（Ｓｙｋ）阻害薬
WO2013081094A1 (ja) * 2011-11-30 2013-06-06 東レ株式会社 イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途
CN104271566B (zh) * 2012-05-22 2017-05-31 霍夫曼-拉罗奇有限公司 取代的联吡啶胺及其用途
JP2014196274A (ja) * 2013-03-29 2014-10-16 三井化学株式会社 多環芳香族炭化水素の誘導体の製造方法
KR102288542B1 (ko) * 2014-12-24 2021-08-11 삼성에스디아이 주식회사 웨어러블 기기의 무선 충전 장치 및 시스템
CN110799190B (zh) 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
WO2019126731A1 (en) * 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP7447098B2 (ja) 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
KR20220097405A (ko) * 2019-11-05 2022-07-07 클라에스 툴린 포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘
WO2021143729A1 (zh) * 2020-01-15 2021-07-22 中国科学院上海药物研究所 多靶点抑制作用化合物、组合物、功能分子及其应用
JP7824282B2 (ja) 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE422799B (sv) * 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
US5891601A (en) * 1996-10-16 1999-04-06 Sumitomo Chemical Company, Ltd. Positive resist composition
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
NZ522793A (en) * 2000-07-04 2005-02-25 Neurosearch As Aryl and heteroaryl diazabicycloalkanes, their preparation and use
JP4303109B2 (ja) * 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
WO2003048137A1 (en) * 2001-11-30 2003-06-12 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
DE60222698T2 (de) * 2001-12-18 2008-06-19 Merck & Co., Inc. Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
DE60223720T2 (de) * 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
EP1458710A4 (en) * 2001-12-21 2005-04-20 Merck & Co Inc Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CA2520863A1 (en) * 2003-04-03 2004-10-14 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
CN100387594C (zh) * 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
EP1613617A4 (en) * 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
CA2425817A1 (en) * 2003-04-17 2004-10-17 Queen's University At Kingston Organic luminescent compounds and methods of making and using same
US20060189661A1 (en) * 2003-11-03 2006-08-24 Wagenen Bradford V Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2555402A1 (en) * 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5

Also Published As

Publication number Publication date
CN1845915A (zh) 2006-10-11
EP1664018A1 (en) 2006-06-07
WO2005021529A1 (en) 2005-03-10
CA2537141A1 (en) 2005-03-10
JP2007504229A (ja) 2007-03-01
US20070027321A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
AU2004268112A1 (en) Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CA2888485C (en) Phenyl linked quinolinyl modulators of ror.gamma.t
JP6445574B2 (ja) ブロモドメイン阻害剤
TWI444378B (zh) 具有β－分泌酶抑制作用之含硫雜環衍生物及其用途
EP2592933B1 (en) Mif inhibitors and their uses
JP2022518860A (ja) 免疫調節剤、組成物およびその使用方法
TW200306180A (en) New compounds
CA3012031C (en) 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
EP3568390A1 (en) Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
WO2003053922A2 (en) Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
JP2005507423A (ja) グリコーゲン合成酵素キナーゼ３ベータ阻害剤（ｇｓｋ３阻害剤）としてのヘテロアリールアミン
CN109219606B (zh) 食欲素受体调节剂的卤素取代的哌啶
CN118055933A (zh) 选择性parp1抑制剂及其应用
WO2004087653A2 (en) 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
KR20160142402A (ko) 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
CN107759620B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
WO2020046975A1 (en) Methods of treating neurodegenerative diseases
JP6977038B2 (ja) Ｇｓｋ−３阻害剤
TW202444351A (zh) 聯芳基衍生物及相關用途
TW202610642A (zh) Pde3a/slfn12干擾物、製備及其用途
JP6787320B2 (ja) テトラヒドロオキセピノピリジン化合物
CA3009485A1 (en) Phenylimidazole compound
TW202434599A (zh) 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑
EA047234B1 (ru) Иммуномодуляторы, композиции и способы с их использованием

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application